Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Dow
Boehringer Ingelheim
McKinsey
Colorcon

Last Updated: February 7, 2023

Details for Patent: 8,946,281


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,946,281 protect, and when does it expire?

Patent 8,946,281 protects ACULAR LS and is included in one NDA.

This patent has five patent family members in three countries.

Summary for Patent: 8,946,281
Title:Ketorolac tromethamine compositions for treating or preventing ocular pain
Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.
Inventor(s): Muller; Christopher A. (Foothill Ranch, CA), Cheetham; Janet K. (Laguna Niguel, CA), Kuan; Teresa H. (Placentia, CA), Power; David F. (Trabuco Canyon, CA)
Assignee: Allergan Sales, LLC (Irvine, CA)
Application Number:13/802,076
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,946,281
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,946,281

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan ACULAR LS ketorolac tromethamine SOLUTION/DROPS;OPHTHALMIC 021528-001 May 30, 2003 AT RX Yes Yes See Plans and Pricing See Plans and Pricing A METHOD OF TREATING OCULAR PAIN See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,946,281

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2468664 See Plans and Pricing
Canada 2967362 See Plans and Pricing
European Patent Office 3217937 See Plans and Pricing
European Patent Office 3777808 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2016077726 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Harvard Business School
McKinsey
Moodys
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.